TRENTON, N.J. (AP) — They were the drugs that were supposed to save the U.S. tens of billions of dollars. Called "biosimilars," they are near-copies of complex and expensive biologic drugs to treat cancer, rare diseases and autoimmune disorders like rheumatoid arthritis and colitis. But U.S. sales...